These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 27124971)

  • 1. [Diagnostics of polycystic ovary syndrome].
    Lazúrová I; Figurová J; Lazúrová Z
    Vnitr Lek; 2015 Dec; 61(12 Suppl 5):5S40-4. PubMed ID: 27124971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diagnostics of polycystic ovary syndrome].
    Lazúrová I; Figurová J; Lazúrová Z
    Vnitr Lek; 2015; 61 Suppl 5():40-4. PubMed ID: 26800472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Prevalence of Polycystic Ovary Syndrome, Its Phenotypes and Cardio-Metabolic Features in a Community Sample of Iranian Population: Tehran Lipid and Glucose Study.
    Farhadi-Azar M; Behboudi-Gandevani S; Rahmati M; Mahboobifard F; Khalili Pouya E; Ramezani Tehrani F; Azizi F
    Front Endocrinol (Lausanne); 2022; 13():825528. PubMed ID: 35299965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis of polycystic ovary syndrome: from NIH criteria to ESHRE-ASRM guidelines.
    Carmina E
    Minerva Ginecol; 2004 Feb; 56(1):1-6. PubMed ID: 14973405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies.
    Sanchez-Garrido MA; Tena-Sempere M
    Mol Metab; 2020 May; 35():100937. PubMed ID: 32244180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity.
    Zeng X; Xie YJ; Liu YT; Long SL; Mo ZC
    Clin Chim Acta; 2020 Mar; 502():214-221. PubMed ID: 31733195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
    Hassa H; Tanir HM; Yildiz Z
    Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New approach to polycystic ovary syndrome and other forms of anovulatory infertility.
    Laven JS; Imani B; Eijkemans MJ; Fauser BC
    Obstet Gynecol Surv; 2002 Nov; 57(11):755-67. PubMed ID: 12447098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polycystic Ovary Syndrome.
    Azziz R
    Obstet Gynecol; 2018 Aug; 132(2):321-336. PubMed ID: 29995717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogenic ovulatory dysfunction or functional female hyperandrogenism: an argument to discard the term polycystic ovary syndrome.
    Behera M; Price T; Walmer D
    Fertil Steril; 2006 Nov; 86(5):1292-5. PubMed ID: 17070182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polycystic ovary syndrome.
    Goudas VT; Dumesic DA
    Endocrinol Metab Clin North Am; 1997 Dec; 26(4):893-912. PubMed ID: 9429864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCOS in adolescence and type 2 diabetes.
    Carreau AM; Baillargeon JP
    Curr Diab Rep; 2015 Jan; 15(1):564. PubMed ID: 25398203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature.
    Azziz R
    J Clin Endocrinol Metab; 2006 Mar; 91(3):781-5. PubMed ID: 16418211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnostic difficulties of polycystic ovarian syndrome in adolescent girls].
    Ságodi L; Barkai L
    Orv Hetil; 2013 Jan; 154(4):136-42. PubMed ID: 23335723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factors.
    Broekmans FJ; Knauff EA; Valkenburg O; Laven JS; Eijkemans MJ; Fauser BC
    BJOG; 2006 Oct; 113(10):1210-7. PubMed ID: 16972863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Contemporary diagnostic criteria for polycystic ovary syndrome].
    Pekhlivanov B; Mitkov M
    Akush Ginekol (Sofiia); 2004; 43(3):55-8. PubMed ID: 15341262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights.
    Westerveld HE; Hoogendoorn M; de Jong AW; Goverde AJ; Fauser BC; Dallinga-Thie GM
    Pharmacol Ther; 2008 Sep; 119(3):223-41. PubMed ID: 18602948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances.
    Spritzer PM
    Arq Bras Endocrinol Metabol; 2014 Mar; 58(2):182-7. PubMed ID: 24830595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of aging on clinical features and metabolic complications of women with polycystic ovary syndrome.
    Falcetta P; Benelli E; Molinaro A; Di Cosmo C; Bagattini B; Del Ghianda S; Salvetti G; Fiore E; Pucci E; Fruzzetti F; Tonacchera M
    J Endocrinol Invest; 2021 Dec; 44(12):2725-2733. PubMed ID: 34089497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower insulin sensitivity differentiates hirsute from non-hirsute Sicilian women with polycystic ovary syndrome.
    Amato MC; Galluzzo A; Merlino S; Mattina A; Richiusa P; Criscimanna A; Giordano C
    Eur J Endocrinol; 2006 Dec; 155(6):859-65. PubMed ID: 17132756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.